Rani Therapeutics (RANI) Projected to Announce Quarterly Earnings on Thursday

Rani Therapeutics (NASDAQ:RANI) is expected to announce its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Rani Therapeutics to announce earnings of ($0.05) per share and revenue of $0.9250 million for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Friday, August 14, 2026 at 4:00 PM ET.

Rani Therapeutics (NASDAQ:RANI) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.02. The business had revenue of $1.71 million during the quarter, compared to analysts’ expectations of $1.12 million. On average, analysts expect Rani Therapeutics to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Rani Therapeutics Stock Performance

Shares of NASDAQ RANI opened at $0.82 on Wednesday. Rani Therapeutics has a fifty-two week low of $0.44 and a fifty-two week high of $3.87. The firm has a market capitalization of $101.58 million, a PE ratio of -2.00 and a beta of 0.78. The stock’s 50-day simple moving average is $0.79 and its 200-day simple moving average is $1.00.

Insider Transactions at Rani Therapeutics

In other news, CEO Talat Imran purchased 35,000 shares of the business’s stock in a transaction on Friday, July 17th. The shares were bought at an average price of $0.72 per share, with a total value of $25,200.00. Following the completion of the transaction, the chief executive officer directly owned 469,736 shares in the company, valued at approximately $338,209.92. This represents a 8.05% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 26.73% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Rani Therapeutics

A number of hedge funds have recently modified their holdings of RANI. OMERS ADMINISTRATION Corp acquired a new position in shares of Rani Therapeutics in the 4th quarter valued at $93,000. Bridgeway Capital Management LLC acquired a new stake in Rani Therapeutics during the 4th quarter worth $155,000. Millennium Management LLC purchased a new position in Rani Therapeutics during the 4th quarter worth $220,000. Citadel Advisors LLC grew its position in Rani Therapeutics by 199.0% during the 3rd quarter. Citadel Advisors LLC now owns 452,542 shares of the company’s stock worth $226,000 after purchasing an additional 301,193 shares during the last quarter. Finally, 683 Capital Management LLC acquired a new position in Rani Therapeutics in the fourth quarter valued at $658,000. 30.19% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on RANI shares. Weiss Ratings downgraded Rani Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, July 17th. Canaccord Genuity Group reissued a “buy” rating and set a $5.00 price objective on shares of Rani Therapeutics in a report on Wednesday, May 20th. Wall Street Zen upgraded shares of Rani Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, May 17th. Finally, Lake Street Capital started coverage on shares of Rani Therapeutics in a report on Tuesday, April 14th. They issued a “buy” rating and a $9.00 target price for the company. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $8.75.

Rani Therapeutics Company Profile

Rani Therapeutics is a clinical-stage biopharmaceutical company developing oral delivery technologies for large-molecule drugs. The company’s proprietary RaniPill platform is designed to enable the gastrointestinal delivery of biologic therapies traditionally administered via injection. Through a swallowable capsule that autonomously deploys a microscopic injector in the small intestine, Rani aims to improve patient convenience and adherence for peptide and protein therapies, including insulin and other hormones.

Since its founding in 2012, Rani Therapeutics has advanced its lead programs through early-phase clinical trials, demonstrating proof-of-concept for oral insulin delivery.